May 15 Bellerophon Therapeutics Inc:
* Bellerophon reports first quarter 2017 financial results and provides business update
* Q1 loss per share $0.60
* Bellerophon Therapeutics - believes that as of march 31, 2017, it has sufficient funds to satisfy its operating cash needs for at least next 12 months
* Bellerophon Therapeutics - at March 31, 2017, co had cash and cash equivalents, restricted cash and marketable securities of $17.1 million compared to $20.5 million at December 31, 2016 Source text for Eikon: Further company coverage:
UPDATE 1-Property markets outlook remains strong as golden age fades -PGIM
NEW YORK, June 27 A golden period in global property markets appears near an end as rising interest rates and lower returns hurt performance, but the outlook for real estate remains strong, asset manager PGIM said on Tuesday.